The lawsuit follows a similar one that Illumina filed earlier this year in Germany against Latvia MGI Tech, another subsidiary of BGI Group.
The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
Both teams had sequencing data generated at BGI and said that going forward, it would be important to validate the technology outside of BGI.
The suit alleges that BGI's sequencing products and reagents infringe a European patent held by Illumina.
At the AGBT conference, MGI Tech showcased its technologies, while a Sanger Institute researcher presented results from a comparison between BGI and Illumina data.
The Shenzhen, China-based BGI subsidiary plans to expand its business to the United Arab Emirates, Qatar, Saudi Arabia, and other countries.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
Paragon and MGI Tech — a unit of BGI — have signed a distribution deal for certain of their respective next-generation sequencing panels and sample prep products.
At the ICG-13 conference, BGI previewed a high-throughput sequencer, MGISEQ-T7, that will be commercially available in 2019 and have a throughput of up to 20,000 genomes per year.
University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.
In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.